Mesenchymal Stem Cells: A Therapeutic Approach to POAG
About the Research Project
Program
Award Type
Standard
Award Amount
$90,000
Active Dates
April 01, 2006 - March 31, 2008
Grant ID
G2006043
Acknowledgement
Summary
Glaucomas are a group of eye diseases that lead to a gradual loss of vision that may result in blindness. There is still no cure for glaucoma, and current treatments consist of methods aimed at restoring the intraocular pressure levels. Argon laser trabeculoplasty has provided an effective therapy for glaucoma. However, the efficiency of laser therapy is limited to a short period of time, and repetitive procedures are usually required. One possible explanation for this limited efficiency is aging. As we get old, the regenerative potential of the tissues is diminished due to the lost and aging of progenitor cells. Results from the laboratory suggest an accumulation of aged cells in the drainage canal of the glaucomatous eye. The accumulation of aged nonfunctional cells may be responsible the limited regenerative potential following laser therapy. Dr. Gonzalez’s hypothesis is that transplantation of young progenitor cells following laser therapy will replace the laser-damaged cells; that these transplanted progenitor cells will repopulate the aged-drainage canal; and that this repopulation will recover the drainage canal functionality. He proposes to explore the use of adult mesenchymal stem cells from the bone marrow as a potential cellular replacement therapeutic strategy combined with laser therapy.
Related Grants
National Glaucoma Research
Maldevelopment of Schlemm's Canal in Children with Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Revathi Balasubramanian, PhD
Current Organization
Columbia University
Maldevelopment of Schlemm's Canal in Children with Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Revathi Balasubramanian, PhD
Current Organization
Columbia University
National Glaucoma Research
Using Artificial Intelligence to Discover Genetic Risk Factors for Glaucoma Worsening
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Nazlee Zebardast, MD, MPH
Current Organization
Massachusetts Eye and Ear Infirmary
Using Artificial Intelligence to Discover Genetic Risk Factors for Glaucoma Worsening
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Nazlee Zebardast, MD, MPH
Current Organization
Massachusetts Eye and Ear Infirmary
National Glaucoma Research
Understanding Optic Nerve Head Astrocyte Contributions to Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Evan Cameron, PhD
Current Organization
Cleveland Clinic - Lerner Research Institute
Understanding Optic Nerve Head Astrocyte Contributions to Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Evan Cameron, PhD
Current Organization
Cleveland Clinic - Lerner Research Institute